PYPD
HEALTHCAREPolypid Ltd
$4.48-0.02 (-0.44%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PYPD Today?
No stock-specific AI insight has been generated for PYPD yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.44$5.12
$4.48
Fundamentals
Market Cap$85M
P/E Ratio—
EPS$-2.09
Dividend Yield—
Dividend / Share—
ROE-3.7%
Profit Margin—
Debt / Equity—
Trading
Volume28K
Avg Volume (10D)—
Shares Outstanding19.1M
PYPD News
20 articles- PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026Yahoo Finance·May 6, 2026
- PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual MeetingYahoo Finance·Apr 28, 2026
- PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026Yahoo Finance·Apr 13, 2026
- PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDAYahoo Finance·Mar 31, 2026
- PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug ApplicationYahoo Finance·Mar 17, 2026
- PolyPid Announces Participation in Upcoming Investor ConferencesYahoo Finance·Feb 25, 2026
- When Will PolyPid Ltd. (NASDAQ:PYPD) Turn A Profit?Yahoo Finance·Feb 13, 2026
- PolyPid Ltd. Q4 2025 Earnings Call SummaryMoby·Feb 12, 2026
- PolyPid Ltd (PYPD) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial ChallengesYahoo Finance·Feb 11, 2026
- PolyPid (PYPD) Q4 2025 Earnings Call TranscriptMotley Fool·Feb 11, 2026
- PolyPid Q4 Earnings Call HighlightsMarketbeat·Feb 11, 2026
- PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial ResultsYahoo Finance·Feb 11, 2026
- PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026Yahoo Finance·Jan 28, 2026
- PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of DirectorsYahoo Finance·Dec 16, 2025
- PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA SubmissionYahoo Finance·Dec 3, 2025
- PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025Yahoo Finance·Nov 25, 2025
- PolyPid Ltd (PYPD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ChallengesYahoo Finance·Nov 12, 2025
- PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial ResultsYahoo Finance·Nov 12, 2025
- PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"Yahoo Finance·Nov 6, 2025
- PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025Yahoo Finance·Oct 29, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$4.50
Day High$0.00
Day Low$0.00
52 Week High$5.12
52 Week Low$2.44
52-Week Range
$2.44$5.12
$4.48
Fundamentals
Market Cap$85M
P/E Ratio—
EPS$-2.09
Dividend Yield—
Dividend / Share—
ROE-3.7%
Profit Margin—
Debt / Equity—
Trading
Volume28K
Avg Volume (10D)—
Shares Outstanding19.1M
About Polypid Ltd
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address unmet medical needs. The company is headquartered in Petah Tikva, Israel.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—